APOB and metabolic syndrome: Interestingly, although DIO+I improved dyslipidemia compared to DIO group (24 weeks), plasmatic apoB100 levels were significantly increased in all groups compared to LFD, suggesting the presence of pro-atherogenic small and dense LDL particles (Figure 2A-2C).